Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Phase 2CompletedNCT00189787

Astellas Pharma Inc370 enrolled

Overview

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

370

Conditions

Asthma, Bronchial Bronchial Asthma

Interventions

tacrolimusDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of asthma * Patients treated with inhaled corticosteroid * FEV1 (forced expiratory volume in 1 second)\>60% to 80% Exclusion Criteria: * Respiratory infection within 2 weeks * Asthma exacerbation within 90 days

Locations (49)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Pleven, Bulgaria

Unnamed facility

Rousse, Bulgaria

Unnamed facility

Sofia, Bulgaria

Unnamed facility

Varna, Bulgaria

Unnamed facility

Brno, Czechia

Unnamed facility

Krhanice, Czechia

Unnamed facility

Olomouc, Czechia

Unnamed facility

Šumperk, Czechia

Unnamed facility

Berlin, Germany

Unnamed facility

Berlin, Germany

...and 39 more locations